Evidence map›Paper›PMID 35807836›Full record

Trial reportNutrients2022

Ameliorating Effect of

Chen-Meng Kuan, Chia-Hua Liang, Wei-Hsiu Chuang, Ting-Yu Lin, Pang-Kuei Hsu

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Nutrients, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Chen-Meng KuanDepartment of Research and Development, Greenyn Biotechnology Co., Ltd., Taichung City 40768, Taiwan.ORCID 0000-0002-7862-5532
Chia-Hua LiangDepartment of Cosmetic Science, Chia Nan University of Pharmacy and Science, Tainan City 71710, Taiwan.
Wei-Hsiu ChuangDepartment of Research and Development, Greenyn Biotechnology Co., Ltd., Taichung City 40768, Taiwan.
Ting-Yu LinDepartment of Research and Development, Greenyn Biotechnology Co., Ltd., Taichung City 40768, Taiwan.
Pang-Kuei HsuDepartment of Research and Development, Greenyn Biotechnology Co., Ltd., Taichung City 40768, Taiwan.
Chia Nan University of Pharmacy and Science · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Crassocephalum rabens (Asteraceae) is a common herb used in Taiwanese folk medicine to treat inflammation-related syndromes. Pharmacological studies have revealed that galactolipids exhibit anti-oxidative, anti-inflammatory, and anti-hyaluronidase activities and improve skin wrinkles, moisture, and elasticity in healthy subjects. However, the anti-aging effects of C. rabens and its primary active compound, 1,2-di-O-linolenoyl-3-O-β-galactopyranosyl-sn-glycerol (dLGG), remain elusive. Here, we investigated whether C. rabens can improve skin conditions in healthy individuals using a double-blind approach. Forty enrolled volunteers were randomly and equally assigned to the control or treatment group and were required to take either a placebo or a C. rabens extract capsule daily for one month. Skin parameters were measured before and after the study. The results showed significant differences in skin elasticity, wrinkles, collagen content, brightness, and hydration between the baseline and week 4 in the treatment group. Particularly, compared with those in the placebo group, skin wrinkles (p < 0.05), brightness (p < 0.001), collagen content (p < 0.01), and UV spots (p < 0.05) were notably improved after treatment with the C. rabens extract. Our study successfully demonstrated the application of C. rabens in preventing skin aging. Further investigations will be conducted to study the underlying anti-aging mechanism of dLGG.

Indexed as

AsteraceaeSkin AgingDouble-Blind MethodHumansPlant ExtractsSkinPlant Extractsanti-agingAsteraceaeCrassocephalum rabensdietary supplementdLGGskin health

Identifiers

PMID35807836
PMCPMC9268076
OpenAlexW4283646943

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.